Get in touch
We are a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for the general population.
Innovating novel solutions for unmet patient and healthcare needs.
The CLINUVEL Group works to translate scientific concepts and breakthroughs into commercial products.
We are determined in our desire to excel scientific research and development, building on our global expertise to deliver lifelong care and novel products for patients and consumers.
The CLINUVEL Group places much emphasis on its People and Environment as central to all of the Group’s working practise. CLINUVEL focuses its research and development on healthcare problems not yet addressed, aiming to deliver innovative medical solutions. Our products seek to prevent or treat acute and chronic medical conditions where no alternatives exist.
The CLINUVEL Group pledges to adhere to a principle set of values, which reflect how we operate and expand our business.
These fall within five main
categories: People & Environment; Technology; Approach; Knowledge Building & Sharing; and Respect & Appreciation.
We work for those who have no alternatives: patients, physicians, at-risk individuals, and our stakeholders.
We are selective and invest time in the talent we employ. We aspire to create an environment where professionals are able to develop and grow. We aim to present skilled talent with early opportunities, responsibilities and accountability as part of training the next generation.
We strive to build international teams and operate on the basis of gender and ethnic equality. We wish to set an example of excellence in our industry.
CLINUVEL announces the development of PRÉNUMBRA® a non-solid (liquid) formulation of afamelanotide for the treatment of acute disorders.
The US Food and Drug Administration (FDA) grants marketing authorization for SCENESSE® (afamelanotide) for adult erythropoietic protoporphyria (EPP) patients.
The European Medicines Agency grants marketing authorisation for SCENESSE® (afamelanotide 16mg) for the prevention of phototoxicity in adult EPP patients.
CLINUVEL conducts its first clinical trial of afamelanotide in adult EPP patients.
The CLINUVEL team in Australia obtains the rights to the technologies and established a company around alpha-MSH, its derivatives and knowledge.
The CLINUVEL story starts in 1987 when university researchers launched an idea of synthesising human hormones to protect the skin. During this period, little was known about the properties of alpha-MSH (melanocyte stimulating hormone)…
Through learning, research, and development, CLINUVEL’s teams became leading global experts in launching innovative therapies and unhinging established views. Success in innovation comes with the complexity and pain of proving novel concepts first, as no other company would have proceeded.
Our employees specialise in several key areas, including:
At CLINUVEL we aim to use our knowledge to innovate products for smaller patient populations and larger audiences.
In our own laboratories, we use active and non-active ingredients for formulating medicines for smaller patient populations (orphan diseases), while knowledge and derivatives of these medicinal products are tested and used for products benefiting a broader audience.
CLINUVEL specialises in the introduction of novel medicinal technology, skin care products and protection under extreme conditions for all.